A Darwinian perspective on tumor immune evasion.


Journal

Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362

Informations de publication

Date de publication:
01 2022
Historique:
received: 17 06 2021
revised: 21 11 2021
accepted: 14 12 2021
pubmed: 22 12 2021
medline: 26 4 2022
entrez: 21 12 2021
Statut: ppublish

Résumé

Evading immune-mediated destruction is a critical step of tumor evolution and the immune system is one of the strongest selective pressures during tumorigenesis. Analyzing tumor immune evasion from a Darwinian perspective may provide critical insight into the mechanisms of primary immune escape and acquired resistance to immunotherapy. Here, we review the steps required to mount an anti-tumor immune response, describe how each of these steps is disrupted during tumorigenesis, list therapeutic strategies to restore anti-tumor immunity, and discuss each mechanism of immune and therapeutic evasion from a Darwinian perspective.

Identifiants

pubmed: 34933050
pii: S0304-419X(21)00169-4
doi: 10.1016/j.bbcan.2021.188671
pmc: PMC8818030
mid: NIHMS1766760
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

188671

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197623
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503256
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Cancer Immunol Res. 2019 Jul;7(7):1148-1161
pubmed: 31088845
Nat Immunol. 2018 Jun;19(6):538-546
pubmed: 29777219
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Eur J Immunol. 2019 Aug;49(8):1140-1146
pubmed: 31257581
Immunity. 2011 Aug 26;35(2):161-8
pubmed: 21867926
Cancer Res. 2010 Nov 1;70(21):8368-77
pubmed: 20940398
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7
pubmed: 19088187
Trends Cancer. 2017 Nov;3(11):797-808
pubmed: 29120755
Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
Nature. 2014 Oct 2;514(7520):54-8
pubmed: 25079331
Oncoimmunology. 2018 Mar 26;7(7):e1445453
pubmed: 29900056
Nat Immunol. 2019 Sep;20(9):1100-1109
pubmed: 31358997
Immunotherapy. 2011 Oct;3(10):1223-33
pubmed: 21995573
Immunol Cell Biol. 2005 Oct;83(5):451-61
pubmed: 16174093
Nature. 2004 Jan 8;427(6970):154-9
pubmed: 14712275
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cancer J. 2017 Jul/Aug;23(4):201-205
pubmed: 28731941
Immunol Rev. 2010 Nov;238(1):12-22
pubmed: 20969581
Cancer Res. 2003 Oct 15;63(20):6784-90
pubmed: 14583474
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Immunol Cell Biol. 2015 Mar;93(3):290-6
pubmed: 25367186
Nature. 2012 Oct 18;490(7420):412-6
pubmed: 23051752
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10746-51
pubmed: 19520829
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Sci Transl Med. 2015 Jan 7;7(269):269rv1
pubmed: 25568072
Immunology. 2019 Jul;157(3):187-189
pubmed: 31225653
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Nat Genet. 2016 Mar;48(3):238-244
pubmed: 26780609
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Nat Commun. 2018 Jan 2;9(1):32
pubmed: 29296022
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Nat Commun. 2017 Oct 6;8(1):793
pubmed: 28986561
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Curr Opin Immunol. 2017 Aug;47:85-92
pubmed: 28755541
Trends Genet. 2009 Jan;25(1):30-8
pubmed: 19054589
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Clin Ther. 2015 Apr 1;37(4):764-82
pubmed: 25823918
Front Immunol. 2021 Jul 20;12:715234
pubmed: 34354714
Cell Res. 2017 Jan;27(1):74-95
pubmed: 28025976
Nature. 2012 Feb 08;482(7385):405-9
pubmed: 22318517
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
Nat Rev Immunol. 2013 May;13(5):309-20
pubmed: 23598650
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Cancer Res. 2013 Jan 15;73(2):617-28
pubmed: 23188505
Curr Opin Immunol. 2015 Jun;34:22-7
pubmed: 25597442
Nat Rev Genet. 2019 Jul;20(7):404-416
pubmed: 30918367
Cancer Cell. 2014 Nov 10;26(5):605-22
pubmed: 25517747
Cancer Immunol Res. 2020 Feb;8(2):192-202
pubmed: 31831634
Mol Cell. 2019 Nov 7;76(3):359-370
pubmed: 31668929
FEBS J. 2016 Jul;283(14):2731-48
pubmed: 26787424
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Front Oncol. 2021 Jan 11;10:614230
pubmed: 33505920
Semin Immunopathol. 2019 Jan;41(1):49-58
pubmed: 30187086
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Annu Rev Med. 2019 Jan 27;70:437-450
pubmed: 30379598
Immun Ageing. 2008 Sep 24;5:11
pubmed: 18816370
Immunol Rev. 2016 May;271(1):200-20
pubmed: 27088916
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
Biophys J. 2020 Feb 4;118(3):565-577
pubmed: 31928762
Cancer Immunol Res. 2020 Jan;8(1):146-154
pubmed: 31719056
Blood. 2008 Apr 1;111(7):3635-43
pubmed: 18223165
J Immunol. 2010 Dec 15;185(12):7452-9
pubmed: 21057081
J Clin Pathol. 2018 Mar;71(3):189-194
pubmed: 29097600
Trends Immunol. 2017 Jun;38(6):432-443
pubmed: 28499492
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
Immunology. 2019 May;157(1):3-12
pubmed: 30897205
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Int Rev Cell Mol Biol. 2019;349:55-151
pubmed: 31759434
Nature. 2015 Feb 19;518(7539):422-6
pubmed: 25470049
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Sci Transl Med. 2012 Mar 28;4(127):127ps8
pubmed: 22461638
Nat Rev Immunol. 2004 Jan;4(1):67-72
pubmed: 14704769
Trends Cell Biol. 2017 Apr;27(4):241-254
pubmed: 27986534
Immunol Cell Biol. 2016 Mar;94(3):236-41
pubmed: 26700072
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Nat Rev Cancer. 2019 Aug;19(8):465-478
pubmed: 31278396
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
World J Gastroenterol. 2018 Dec 28;24(48):5418-5432
pubmed: 30622371
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Cancer Res. 2005 Nov 15;65(22):10139-44
pubmed: 16287995
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Biochim Biophys Acta. 2016 Apr;1865(2):168-75
pubmed: 26868867
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Cell. 2017 Mar 13;31(3):311-325
pubmed: 28292435
Oncotarget. 2017 Nov 25;8(66):110693-110707
pubmed: 29299180
Cancer Lett. 2018 Apr 10;419:210-221
pubmed: 29414305
Trends Cell Biol. 2019 Jul;29(7):569-579
pubmed: 30987806
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Immunity. 2018 Feb 20;48(2):202-213
pubmed: 29466753
EMBO J. 2021 Sep 15;40(18):e108389
pubmed: 34459009
Trends Cancer. 2016 May;2(5):263-276
pubmed: 28741512
Immunity. 2014 Nov 20;41(5):694-707
pubmed: 25517612
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Immunity. 2019 Apr 16;50(4):871-891
pubmed: 30995504
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Ann N Y Acad Sci. 2018 Apr;1417(1):104-115
pubmed: 29566262
Nature. 2019 Mar;567(7749):479-485
pubmed: 30894752
Mol Cancer. 2019 Aug 23;18(1):128
pubmed: 31443694
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Nat Med. 2019 Oct;25(10):1488-1499
pubmed: 31591590
J Virol. 2005 Mar;79(6):3675-83
pubmed: 15731261
J Hematol Oncol. 2019 Sep 6;12(1):93
pubmed: 31492199
Semin Immunopathol. 2019 May;41(3):327-337
pubmed: 30989321
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Mol Oncol. 2014 Sep 12;8(6):1132-9
pubmed: 25106088
Cancer Res. 2014 Dec 15;74(24):7168-74
pubmed: 25477332

Auteurs

Julieann Puleo (J)

Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.

Kornelia Polyak (K)

Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH